SDLT arm | MAP/CB-CAPs testing arm | |
Number of patients | 73 | 72 |
Age (years) | 48.4±1.6 | 50.0±1.8 |
Gender (% females) | 94.5% | 93.1% |
Ethnicities | ||
Caucasians (%) | 67.1% | 73.6% |
African Americans (%) | 24.7% | 18.1% |
Asians (%) | 2.7% | 2.8% |
Others (%) | 5.5% | 5.6% |
Days since referral* | 28±3 | 33±3 |
ANA (historical, %)† | 100% | 100% |
PGA (0–3 point) | 1.1±0.1 | 1.2±0.1 |
EQ5D-5L‡ | 0.767±0.015 | 0.764±0.019 |
Likelihood of SLE (0–5 points) | 1.42±0.06 | 1.46±0.06 |
Prednisone (%) | 5.5% | 5.6% |
Hydroxychloroquine (%) | 9.6% | 13.9% |
Results are expressed as average (SEM) and percent as appropriate.
*Per protocol, all patients were referred to the rheumatologist for less than 3 months.
†Per protocol, all patients had ahistory of ANA positivity.
‡EQ5D-5L was available in 64 and 66 patients randomised to SDLT and MAP/CB-CAPs arm, respectively.
CB-CAP, cell-bound complement activation products; EQ5D-5L, five-level EuroQol five-dimensional questionnaire; MAP, multianalyte assay panel; PGA, physician global assessment; SDLT, standard diagnosis laboratory testing.